Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study. Issue 5 (31st January 2023)

• Record Type: Journal Article
• Authors: Artico, Jessica; Shiwani, Hunain; Moon, James C.; Gorecka, Miroslawa; McCann, Gerry P.; Roditi, Giles; Morrow, Andrew; Mangion, Kenneth; Lukaschuk, Elena; Shanmuganathan, Mayooran; Miller, Christopher A.; Chiribiri, Amedeo; Prasad, Sanjay K.; Adam, Robert D.; Singh, Trisha; Bucciarelli-Ducci, Chiara; Dawson, Dana; Knight, Daniel; Fontana, Marianna; Manisty, Charlotte; Treibel, Thomas A.; Levelt, Eylem; Arnold, Ranjit; Macfarlane, Peter W.; Young, Robin; McConnachie, Alex; Neubauer, Stefan; Piechnik, Stefan K.; Davies, Rhodri H.; Ferreira, Vanessa M.; Dweck, Marc R.; Berry, Colin; Greenwood, John P.;
• Is Part Of: Circulation. Volume 147:Issue 5(2023)
• Page Start: 364
• Page End: 374
• Publication Date: 2023-01-31
• Subjects: cardiovascular diseases -- coronavirus -- COVID-19 -- magnetic resonance imaging -- myocardial infarction -- troponin; Blood -- Circulation -- Periodicals; Cardiovascular system -- Periodicals; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; 616.1
• DOI: 10.1161/CIRCULATIONAHA.122.060632
• Languages: English
• ISSNs: 0009-7322

Abstract

Abstract : Background: Acute myocardial injury in hospitalized patients with coronavirus disease 2019 (COVID-19) has a poor prognosis. Its associations and pathogenesis are unclear. Our aim was to assess the presence, nature, and extent of myocardial damage in hospitalized patients with troponin elevation. Methods: Across 25 hospitals in the United Kingdom, 342 patients with COVID-19 and an elevated troponin level (COVID+/troponin+) were enrolled between June 2020 and March 2021 and had a magnetic resonance imaging scan within 28 days of discharge. Two prospective control groups were recruited, comprising 64 patients with COVID-19 and normal troponin levels (COVID+/troponin−) and 113 patients without COVID-19 or elevated troponin level matched by age and cardiovascular comorbidities (COVID−/comorbidity+). Regression modeling was performed to identify predictors of major adverse cardiovascular events at 12 months. Results: Of the 519 included patients, 356 (69%) were men, with a median (interquartile range) age of 61.0 years (53.8, 68.8). The frequency of any heart abnormality, defined as left or right ventricular impairment, scar, or pericardial disease, was 2-fold greater in cases (61% [207/342]) compared with controls (36% [COVID+/troponin−] versus 31% [COVID−/comorbidity+]; P <0.001 for both). More cases than controls had ventricular impairment (17.2% versus 3.1% and 7.1%) or scar (42% versus 7% and 23%; P <0.001 for both). The myocardial injury pattern was different, with cases more likely than controls to have infarction (13% versus 2% and 7%; P <0.01) or microinfarction (9% versus 0% and 1%; P <0.001), but there was no difference in nonischemic scar (13% versus 5% and 14%; P =0.10). Using the Lake Louise magnetic resonance imaging criteria, the prevalence of probable recent myocarditis was 6.7% (23/342) in cases compared with 1.7% (2/113) in controls without COVID-19 ( P =0.045). During follow-up, 4 patients died and 34 experienced a subsequent major adverse cardiovascular event (10.2%), which was similar to controls (6.1%; P =0.70). Myocardial scar, but not previous COVID-19 infection or troponin, was an independent predictor of major adverse cardiovascular events (odds ratio, 2.25 [95% CI, 1.12–4.57]; P =0.02). Conclusions: Compared with contemporary controls, patients with COVID-19 and elevated cardiac troponin level have more ventricular impairment and myocardial scar in early convalescence. However, the proportion with myocarditis was low and scar pathogenesis was diverse, including a newly described pattern of microinfarction. Registration: URL: https://www.isrctn.com ; Unique identifier: 58667920.